for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Jinyu Bio-Technology Co Ltd

600201.SS

Latest Trade

19.09CNY

Change

-0.19(-0.99%)

Volume

14,238,045

Today's Range

18.90

 - 

19.28

52 Week Range

14.11

 - 

21.98

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
19.28
Open
19.28
Volume
14,238,045
3M AVG Volume
407.34
Today's High
19.28
Today's Low
18.90
52 Week High
21.98
52 Week Low
14.11
Shares Out (MIL)
1,098.79
Market Cap (MIL)
21,499.93
Forward P/E
50.32
Dividend (Yield %)
1.83

Next Event

Jinyu Bio-Technology Co Ltd Annual Shareholders Meeting

Latest Developments

More

Jinyu Bio-Technology's 9-Month Net Profit Down 63.5% Y/Y

Jinyu Bio-Technology Says Board Elects Zhang Chongyu As Chairman

Jinyu Bio-Technology Says 9-Month Net Profit Down 0.2 Percent Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Jinyu Bio-Technology Co Ltd

JINYU BIO-TECHNOLOGY CO., LTD. formerly INNER MONGOLIA JINYU GROUP CO., LTD, is a China-based company, principally engaged in the research and development, manufacture and sales of veterinary biopharmaceuticals. The Company mainly provides veterinary vaccines. The Company is also engaged in textile processing business, and the provision of property leasing and management activities. The Company also provides energy products.

Industry

Biotechnology & Drugs

Contact Info

No. 58, Ordos West Street

+86.471.6539434

http://www.jinyu.com.cn

Executive Leadership

Chongyu Zhang

Chairman of the Board, President

Xianming Xu

Vice Chairman of the Board

Hongmei Zhang

Chief Financial Officer

Songtao Yin

Vice President, Secretary of the Board

Xiu Hua Wang

Vice President, Director

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

1.5K

2018

1.9K

2019(E)

1.2K
EPS (CNY)

2016

2.020

2018

0.660

2019(E)

0.355
Price To Earnings (TTM)
67.13
Price To Sales (TTM)
16.38
Price To Book (MRQ)
4.38
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.10
LT Debt To Equity (MRQ)
1.10
Return on Investment (TTM)
6.31
Return on Equity (TTM)
5.44

Latest News

Latest News

BRIEF-Jinyu Bio-Technology Says 2017 Net Profit Up 35.0 Percent Y/Y

* SAYS 2017 NET PROFIT UP 35.0 PERCENT Y/Y Source text in Chinese: https://bit.ly/2r4zt8W Further company coverage: (Reporting by Hong Kong newsroom)

China stocks little changed, developers offset healthcare gains

* FTSE China A50 -0.6 pct, BNY Mellon ADR China Select Index +1.8 pct

BRIEF-Jinyu Bio-Technology to raise stake in animal vaccine firm to 47 pct

* Says co signs agreement to invest in animal vaccine firm Liaoning Yikang Biological (target firm) in exchange for 40 million shares and to acquire 14 million shares from its shareholders, with transaction amount of 403 million yuan in total

BRIEF-Jinyu Bio-Technology's 9-month net profit up 40.7 pct y/y

* Says 9-month net profit up 40.7 percent y/y at 682.6 million yuan ($102.80 million)

BRIEF-Jinyu Bio-Technology says 2017 H1 A share dividend payment

* Says it will use additional paid-in capital to distribute 0.4 shares for every one share for 2017 H1, to shareholders of A shares recorded on Sept. 29

BRIEF-Jinyu Bio-Technology's H1 net profit up 36.5 pct y/y

* Says H1 net profit up 36.5 percent y/y at 387.3 million yuan ($58.21 million)

BRIEF-Jinyu Bio-Technology to pay A shares annual div for FY 2016 on June 12

* Says it will pay cash dividend of 0.50 yuan(before tax)/share for 2016 to shareholders of record on June 9

BRIEF-Jinyu Bio-Technology to pay cash 5 yuan per 10 shares as FY 2016 div payment

* Says it plans to pay cash 5 yuan per 10 shares as FY 2016 div payment

BRIEF-Jinyu Bio-Technology's Q1 net profit up after 2016 rise

* Says 2016 net profit up 34.4 percent y/y at 644.5 million yuan ($93.62 million)

BRIEF-Jinyu Bio-Technology's trading in shares to halt pending announcement

* Says trading in shares to halt from April 21 pending announcement related to stock ownership incentives

BRIEF-Jinyu Bio-technology receives administrative order

* Says it received an administrative order from Inner Mongolia Regulatory Bureau of China Securities Regulatory Commission, regarding information disclosure

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up